Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial

B. Odler, R. Riedl, D. Geetha, WM. Szpirt, C. Hawley, L. Uchida, ZS. Wallace, G. Walters, E. Muso, V. Tesar, CD. Pusey, MA. Little, PA. Merkel, M. Walsh, DRW. Jayne, A. Kronbichler, PEXIVAS Investigators

. 2025 ; 107 (3) : 558-567. [pub] 20241219

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009725

Therapeutic plasma exchange (PLEX) is an adjunctive treatment for patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and kidney involvement. Little is known about the effect of PLEX on early changes in kidney function. This post-hoc analysis of the PEXIVAS trial investigated the effects of PLEX on changes in kidney function within 12 months. PEXIVAS was a randomized controlled trial recruiting 691 patients with ANCA-associated glomerulonephritis, of whom 349 underwent PLEX and 342 received no-PLEX. The primary outcomes of this post hoc study of PEXIVAS were change in estimated glomerular filtration rate (eGFR) from baseline and recovery of kidney function (defined as eGFR increase of 15ml/min/1.73m2 or more). Baseline eGFR was 21.7 ± 20.3 and 20.6 ± 18.7 ml/min/1.73m2 in the PLEX and no-PLEX groups, respectively. Mean improvements in eGFR at weeks two, four, and eight after initiation of therapy were greater for the PLEX vs. the no-PLEX groups. The greatest significant difference in recovery of kidney function in the PLEX compared to the no-PLEX groups was at week four (relative risk (RR): 1.41; 95% confidence interval:1.09-1.82). Increased eGFR or recovery of kidney function at week four were significantly associated with lower risk for end-stage kidney disease at week 52 (RR: 0.96: 0.95-0.97, and RR: 0.29: 0.16-0.52; respectively). Neither changes in eGFR nor recovery of kidney function differed by reduced- compared to standard-dose glucocorticoid group. Overall, our study indicates that PLEX improves early kidney function in patients with ANCA-associated glomerulonephritis.

Department of Immunology and Inflammation Imperial College London London UK

Department of Internal Medicine 4 Nephrology and Hypertension Medical University of Innsbruck Innsbruck Austria

Department of Medicine McMaster University Hamilton Ontario Canada

Department of Medicine University of Cambridge Cambridge UK

Department of Nephrology 1st Faculty of Medicine and General University Hospital Charles University Prague Czech Republic

Department of Nephrology and Dialysis Medical Research Institute Kitano Hospital PIIF Tazuke Kofukai Osaka Japan

Department of Nephrology Rigshospitalet University of Copenhagen Copenhagen Denmark

Department of Renal Medicine Canberra Hospital Canberra Australian Capital Territory Australia

Division of Epidemiology Department of Biostatistics Epidemiology and Informatics University of Pennsylvania Philadelphia Pennsylvania USA

Division of Nephrology Department of Internal Medicine Medical University of Graz Graz Austria

Division of Nephrology Johns Hopkins University Baltimore Maryland USA

Division of Rheumatology Allergy and Immunology Mongan Institute Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA

Division of Rheumatology Department of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

Institute for Medical Informatics Statistics and Documentation Medical University of Graz Graz Austria

Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton Ontario Canada

The Australasian Kidney Trials Network Centre for Health Services Research University of Queensland Brisbane Australia

Trinity Kidney Centre Trinity Translational Medicine Institute Trinity College Dublin Dublin Ireland

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009725
003      
CZ-PrNML
005      
20250429135052.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.kint.2024.11.029 $2 doi
035    __
$a (PubMed)39708998
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Odler, Balazs $u Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; Department of Medicine, University of Cambridge, Cambridge, UK
245    14
$a The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial / $c B. Odler, R. Riedl, D. Geetha, WM. Szpirt, C. Hawley, L. Uchida, ZS. Wallace, G. Walters, E. Muso, V. Tesar, CD. Pusey, MA. Little, PA. Merkel, M. Walsh, DRW. Jayne, A. Kronbichler, PEXIVAS Investigators
520    9_
$a Therapeutic plasma exchange (PLEX) is an adjunctive treatment for patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and kidney involvement. Little is known about the effect of PLEX on early changes in kidney function. This post-hoc analysis of the PEXIVAS trial investigated the effects of PLEX on changes in kidney function within 12 months. PEXIVAS was a randomized controlled trial recruiting 691 patients with ANCA-associated glomerulonephritis, of whom 349 underwent PLEX and 342 received no-PLEX. The primary outcomes of this post hoc study of PEXIVAS were change in estimated glomerular filtration rate (eGFR) from baseline and recovery of kidney function (defined as eGFR increase of 15ml/min/1.73m2 or more). Baseline eGFR was 21.7 ± 20.3 and 20.6 ± 18.7 ml/min/1.73m2 in the PLEX and no-PLEX groups, respectively. Mean improvements in eGFR at weeks two, four, and eight after initiation of therapy were greater for the PLEX vs. the no-PLEX groups. The greatest significant difference in recovery of kidney function in the PLEX compared to the no-PLEX groups was at week four (relative risk (RR): 1.41; 95% confidence interval:1.09-1.82). Increased eGFR or recovery of kidney function at week four were significantly associated with lower risk for end-stage kidney disease at week 52 (RR: 0.96: 0.95-0.97, and RR: 0.29: 0.16-0.52; respectively). Neither changes in eGFR nor recovery of kidney function differed by reduced- compared to standard-dose glucocorticoid group. Overall, our study indicates that PLEX improves early kidney function in patients with ANCA-associated glomerulonephritis.
650    _2
$a lidé $7 D006801
650    12
$a ANCA-asociované vaskulitidy $x patofyziologie $x terapie $x farmakoterapie $x komplikace $x imunologie $x diagnóza $7 D056648
650    12
$a hodnoty glomerulární filtrace $7 D005919
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a glukokortikoidy $x terapeutické užití $x aplikace a dávkování $7 D005938
650    12
$a výměna plazmy $7 D010951
650    _2
$a senioři $7 D000368
650    12
$a ledviny $x patofyziologie $x účinky léků $7 D007668
650    12
$a glomerulonefritida $x patofyziologie $x imunologie $x terapie $x krev $7 D005921
650    _2
$a výsledek terapie $7 D016896
650    _2
$a obnova funkce $7 D020127
650    _2
$a dospělí $7 D000328
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Riedl, Regina $u Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria
700    1_
$a Geetha, Duvuru $u Division of Nephrology, Johns Hopkins University, Baltimore, Maryland, USA
700    1_
$a Szpirt, Wladimir M $u Department of Nephrology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Hawley, Carmel $u The Australasian Kidney Trials Network (AKTN), Centre for Health Services Research, University of Queensland, Brisbane, Australia
700    1_
$a Uchida, Lisa $u Department of Medicine, University of Cambridge, Cambridge, UK
700    1_
$a Wallace, Zachary S $u Division of Rheumatology, Allergy, and Immunology, Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
700    1_
$a Walters, Giles $u Department of Renal Medicine, Canberra Hospital, Canberra, Australian Capital Territory, Australia
700    1_
$a Muso, Eri $u Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, Osaka, Japan
700    1_
$a Tesar, Vladimir $u Department of Nephrology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Pusey, Charles D $u Department of Immunology and Inflammation, Imperial College London, London, UK
700    1_
$a Little, Mark A $u Trinity Kidney Centre, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland
700    1_
$a Merkel, Peter A $u Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA
700    1_
$a Walsh, Michael $u Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
700    1_
$a Jayne, David R W $u Department of Medicine, University of Cambridge, Cambridge, UK
700    1_
$a Kronbichler, Andreas $u Department of Internal Medicine IV, Nephrology and Hypertension, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: andreas.kronbichler@i-med.ac.at
710    2_
$a PEXIVAS Investigators
773    0_
$w MED00010141 $t Kidney international $x 1523-1755 $g Roč. 107, č. 3 (2025), s. 558-567
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39708998 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135048 $b ABA008
999    __
$a ok $b bmc $g 2311226 $s 1246806
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 107 $c 3 $d 558-567 $e 20241219 $i 1523-1755 $m Kidney international $n Kidney Int $x MED00010141
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...